Orforglipron: A novel, non-peptide GLP-1 receptor agonist (GLP-1RA) developed for oral administration, orforglipron has shown promise in managing diabetes and obesity. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.